Pre- and post-transplant antiviral therapy (HBV, HCV)

Visceral Medicine

Volumn 32, Issue 2, 2016, Pages 105-109

  Welker, Martin Walter ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

HBV; HCV; Hepatitis B virus; Hepatitis C virus; Liver transplantation; LTX

Indexed keywords

ADEFOVIR; DACLATASVIR; DASABUVIR; ENTECAVIR; IMMUNOGLOBULIN; LAMIVUDINE; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR PLUS VELPATASVIR; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD;

EID: 85029912505     PISSN: 22974725     EISSN: 2297475X     Source Type: Journal    
DOI: 10.1159/000445152     Document Type: Review

References (70)

1. Dienstag JL: Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
2. World Health Organization: Hepatitis B. 2015. www.who.int/mediacentre/factsheets/fs204/en/.
3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-1555.
4. Lavanchy D: The global burden of hepatitis C. Liver Int 2009; 29(suppl 1):74-81.
5. Hope VD, Eramova I, Capurro D, Donoghoe MC: Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2013; 142: 270-286.
6. Shukla A, Vadeyar H, Rela M, Shah S: Liver transplantation: East versus West. J Clin Exp Hepatol 2013; 3: 243-253.
7. Schoening WN, Buescher N, Rademacher S, et al: Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transpl 2013; 13: 2384-2394.
8. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L: Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886-897.
9. European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
10. Cornberg M, Protzer U, Petersen J, et al: Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline (article in German). Z Gastroenterol 2011; 49: 871-930.
11. Sarrazin C, Berg T, Buggisch P, et al: S3 guideline hepatitis C addendum (article in German). Z Gastroenterol 2015; 53: 320-334.
12. European Association for the Study of the Liver: EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
13. Adam R, Karam V, Delvart V, et al: Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688.
14. Camci C, Gurakar A, Rose J, et al: Liver transplantation for hepatitis B in the United States. Transplant Proc 2005; 37: 4350-4353.
15. Shouval D, Samuel D: Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
16. Waki K, Sugawara Y, Tamura S, et al: Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data. Transplantation 2011; 92: 809-814.
17. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A: Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
18. Liaw Y-F, Sung JJY, Chow WC, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
19. Di Marco V, Marzano A, Lampertico P, et al: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-891.
20. Zhang X, Liu L, Zhang M, et al: The efficacy and safety of entecavir in patients with chronic hepatitis B-associated liver failure: a meta-analysis. Ann Hepatol 2015; 14: 150-160.
21. Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240.
22. Miquel M, Núñez Ó, Trapero-Marugán M, et al: Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013; 12: 205-212.
23. Liaw Y-F, Sheen I-S, Lee C-M, et al: Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
24. Shim JH, Lee HC, Kim KM, et al: Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182.
25. Villeneuve JP, Condreay LD, Willems B, et al: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210.
26. Chan HLY, Chen YC, Gane EJ, et al: Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743.
27. Singal AK, Fontana RJ: Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012; 35: 674-689.
28. Lucey MR, Graham DM, Martin P, et al: Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390-1396.
29. Samuel D, Muller R, Alexander G, et al: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
30. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H: Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
31. Katz LH, Paul M, Guy DG, Tur-Kaspa R: Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308.
32. Ishigami M, Ogura Y, Hirooka Y, Goto H: Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2015; 21: 10290-10298.
33. Harmanci Ö, Selçuk H, Haberal M: Prophylaxis against recurrence in liver transplantation patients with hepatitis B virus: what is new? J Clin Transl Hepatol 2014; 2: 259-265.
34. Xi Z-F, Xia Q: Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21: 829-835.
35. Yoshizawa A, Yamashiki N, Ueda Y, et al: Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res 2015; DOI: 10.1111/hepr.12586.
36. Kim WR, Lake JR, Smith JM, et al: OPTN/SRTR 2013 Annual Data Report: liver. Am J Transpl 2015; 15 (suppl 2):1-28.
37. Taniguchi M: Liver transplantation in the MELD era - analysis of the OPTN/UNOS registry. Clin Transpl 2012; 41-65.
38. Ferenci P, Kozbial K, Mandorfer M, Hofer H: HCV targeting of patients with cirrhosis. J Hepatol 2015; 63: 1015-1022.
39. Charlton M, Everson GT, Flamm SL, et al: Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-659.
40. Curry MP, O'Leary JG, Bzowej N, et al: Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-2628.
41. Afdhal N, Everson G, Calleja JL, et al: Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014; 60:S28.
42. Poordad F, Schiff ER, Vierling JM, et al: Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 2016;DOI: 10.1002/hep.28446.
43. Manns M, Samuel D, Gane EJ, et al.; SOLAR-2 Investigators: Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicenter open-label, randomized, phase 2 trial. Lancet Infect Dis 2016;DOI: 10.1016/S1473-3099(16)00052-9.
44. Welzel T, Petersen J, Gschwantler M, et al: Daclatasvir plus sofosbuvir with or without ribavirin in patients infected with HCV genotype 3: interim results of a multicenter compassionate use program in Europe. Z Gastroenterol 2015; 53:KG150.
45. Hezode C, de Ledinghen V, Fontaine H, et al: Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. J Hepatol 2015; 62(suppl 2): S265-266.
46. Shiffman ML, James AM, Long AG, Alexander PC: Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol 2015; 110: 1179-1185.
47. Modi AA, Nazario H, Trotter JF, et al: Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl 2016; 22: 281-286.
48. Punzalan CS, Barry C, Zacharias I, et al: Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant 2015; 29: 1105-1111.
49. Lawitz E, Sulkowski MS, Ghalib R, et al: Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
50. Stine JG, Intagliata N, Shah NL, et al: Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2014; 60: 1031-1035.
51. Soriano V, Barreiro P, de Mendoza C, Peña JM: Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther 2016; 21: 91-92.
52. U.S. Food and Drug Administration: Hepatitis C treatments Viekira Pak and Technivie: drug safety communication - risk of serious liver injury. www.fda.gov/downloads/Drugs/DrugSafety/UCM468755.pdf.
53. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J: Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-1624.
54. Iacobellis A, Siciliano M, Perri F, et al: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212.
55. Rincon D, Ripoll C, Lo Iacono O, et al: Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101: 2269-2274.
56. Roberts S, Gordon A, McLean C, et al: Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 932-937.
57. Ruiz I, Feray C, Pawlotsky J-M, Hézode C: Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir- based treatment. Liver Transpl 2015; 21: 408-409.
58. Coilly A, Pageaux G, Houssel-Debry P, et al: Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? Hepatology 2015; 51(suppl):275A.
59. Curry MP, Forns X, Chung RT, et al: Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.e1.
60. Gane EJ: The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14(suppl 2): S36-44.
61. Peveling-Oberhag J, Zeuzem S, Hofmann WP: Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10.
62. Ikegami T, Yoshizumi T, Shirabe K, Maehara Y: Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation. J Hepatol 2014; 60: 894-896.
63. Pungpapong S, Aqel BA, Koning L, et al: Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
64. Berenguer M: Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
65. Reddy KR, Everson GT, Flamm SL, et al: Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. AASLD 2014, Boston. Hepatology 2014; 60(suppl 4):200A.
66. Gutierrez JA, Carrion AF, Avalos D, et al: Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21: 823-830.
67. Kwo PY, Mantry PS, Coakley E, et al.: An interferonfree antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382.
68. Charlton M, Gane E, Manns MP, et al: Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2014; 148: 108-117.
69. Pungpapong S, Aqel B, Leise M, et al: Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886.
70. Brown RS, O'Leary JG, Reddy KR, et al: Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2016; 22: 24-33.